CPMG

Ossium Health, Inc. is engaged in the development and manufacturing of cell therapy products aimed at treating leukemia, other blood cancers, and tissue damage, as well as addressing radiation poisoning. The company offers a range of innovative therapies, including HPC, Marrow, which features HLA-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients; Chimera, which enhances organ transplantation; and Chymalis, composed of mesenchymal stem cells that promote the healing of damaged bone and muscle tissue. Additionally, Ossium provides bone marrow cells for research purposes in oncology and immunology. Founded in 2016 and headquartered in San Francisco, California, Ossium Health focuses on improving health outcomes and longevity through advanced bioengineering techniques.

Augmedics Ltd. is a company that specializes in augmented reality surgical guidance systems, aiming to enhance the safety and effectiveness of surgical procedures. Founded in 2014 and headquartered in Yoqneam Ilit, Israel, with an additional office in Chicago, Illinois, the company has developed the xvision-spine (XVS) system. This innovative system features a head-mounted display that allows surgeons to visualize a patient's anatomy through skin and tissue, providing real-time insights into the position of surgical tools and illuminating the surgical area. By integrating advanced technologies, Augmedics seeks to transform surgical treatment and improve patient outcomes during complex operations.

LeafLink operates a wholesale management platform designed to connect cannabis brands and retailers, facilitating streamlined ordering processes, simplified communication, and reduced administrative tasks. The company's platform offers tools for driving brand awareness, boosting sales, tracking orders, engaging with customers, and managing logistics partners. LeafLink serves over 1,200 brands and 3,500 retailers across 22 territories in the US and Canada. Founded in 2015 and headquartered in New York, LeafLink also maintains offices in Los Angeles, San Francisco, Denver, Austin, and Toronto.

Kindred Motorworks specializes in modernizing vintage vehicles by integrating new powertrains, safety features, and contemporary technologies while preserving their classic aesthetics. The company meticulously prototypes and evaluates design decisions to enhance performance and reliability in each model. By incorporating features such as disc brakes and Bluetooth sound systems, Kindred Motorworks transforms internal combustion cars into electric versions, allowing customers to enjoy modern functionality without compromising the original design. This innovative approach not only revitalizes classic cars but also aligns with the growing demand for sustainable transportation solutions.

Provi is a Chicago-based company that operates the largest online marketplace for the wholesale alcohol industry, simplifying the ordering process by connecting buyers, distributors, and suppliers. Founded in 2016, Provi's platform enhances communication and efficiency for both on-premise and off-premise buyers, including liquor stores, bars, and restaurants. By centralizing the ordering process, Provi enables users to order directly from alcohol distributors while providing tools for order tracking and analytics. As of 2022, the marketplace includes about 10 percent of licensed retailers in the U.S. Provi has received significant funding, totaling $125 million, and has been recognized for its workplace culture. The company also formed a partnership with SevenFifty to further enhance its offerings.

PROCEPT BioRobotics Corporation is a surgical robotics company based in Redwood Shores, California, that specializes in developing innovative solutions for urology. The company is known for its AquaBeam Robotic System, an advanced, image-guided surgical robot designed for minimally invasive procedures, particularly for treating benign prostatic hyperplasia (BPH). BPH affects approximately 40 million men in the United States and can lead to lower urinary tract symptoms (LUTS). PROCEPT's Aquablation therapy aims to provide effective and durable treatment outcomes that are not influenced by prostate size or the surgeon's experience. The company has established a robust body of clinical evidence, including nine clinical studies and over 100 peer-reviewed publications, demonstrating the clinical advantages of its Aquablation therapy. Revenue is primarily generated through the sales of the AquaBeam Robotic System and its disposable handpieces.

Provi is a Chicago-based company that operates the largest online marketplace for the wholesale alcohol industry, simplifying the ordering process by connecting buyers, distributors, and suppliers. Founded in 2016, Provi's platform enhances communication and efficiency for both on-premise and off-premise buyers, including liquor stores, bars, and restaurants. By centralizing the ordering process, Provi enables users to order directly from alcohol distributors while providing tools for order tracking and analytics. As of 2022, the marketplace includes about 10 percent of licensed retailers in the U.S. Provi has received significant funding, totaling $125 million, and has been recognized for its workplace culture. The company also formed a partnership with SevenFifty to further enhance its offerings.

PROCEPT BioRobotics Corporation is a surgical robotics company based in Redwood Shores, California, that specializes in developing innovative solutions for urology. The company is known for its AquaBeam Robotic System, an advanced, image-guided surgical robot designed for minimally invasive procedures, particularly for treating benign prostatic hyperplasia (BPH). BPH affects approximately 40 million men in the United States and can lead to lower urinary tract symptoms (LUTS). PROCEPT's Aquablation therapy aims to provide effective and durable treatment outcomes that are not influenced by prostate size or the surgeon's experience. The company has established a robust body of clinical evidence, including nine clinical studies and over 100 peer-reviewed publications, demonstrating the clinical advantages of its Aquablation therapy. Revenue is primarily generated through the sales of the AquaBeam Robotic System and its disposable handpieces.

Theatro is a software company that specializes in developing business applications designed for wearable computing devices aimed at enhancing the productivity and communication of the indoor mobile workforce. Initially focusing on the retail and hospitality sectors, Theatro provides a suite of solutions that includes cloud services, wearable computers, and analytics tools. These offerings enable real-time management and information dissemination for employees in fast-paced environments. Theatro's platform utilizes artificial intelligence and voice-controlled technology to facilitate efficient communication and operational management in brick-and-mortar businesses, thereby optimizing employee performance and sales operations. The company, founded in 2011, is headquartered in Dallas, Texas, with an additional office in Bengaluru, India.

PROCEPT BioRobotics Corporation is a surgical robotics company based in Redwood Shores, California, that specializes in developing innovative solutions for urology. The company is known for its AquaBeam Robotic System, an advanced, image-guided surgical robot designed for minimally invasive procedures, particularly for treating benign prostatic hyperplasia (BPH). BPH affects approximately 40 million men in the United States and can lead to lower urinary tract symptoms (LUTS). PROCEPT's Aquablation therapy aims to provide effective and durable treatment outcomes that are not influenced by prostate size or the surgeon's experience. The company has established a robust body of clinical evidence, including nine clinical studies and over 100 peer-reviewed publications, demonstrating the clinical advantages of its Aquablation therapy. Revenue is primarily generated through the sales of the AquaBeam Robotic System and its disposable handpieces.

Apollo Endosurgery, Inc. is a medical technology company based in Austin, Texas, specializing in the design, development, and commercialization of innovative medical devices for gastrointestinal health. Founded in 2005, the company focuses on advancing therapeutic endoscopy as a less invasive alternative to traditional surgical procedures, thereby reducing complication rates and overall healthcare costs. Its product portfolio includes the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which enable physicians to place full-thickness sutures and secure tissue approximation through flexible endoscopy. Additionally, Apollo offers the X-Tack Endoscopic HeliX Tacking System and the Orbera Intragastric Balloon, which aids in weight management by reducing stomach capacity. The company's devices cater to gastroenterologists and bariatric surgeons, addressing various gastrointestinal conditions such as acute perforations and chronic fistulas. Apollo Endosurgery's commitment to innovation is rooted in the collaborative efforts of a distinguished group of gastroenterologists and surgeons who aimed to enhance the field of therapeutic endoscopy.

Reata Pharmaceuticals is a clinical-stage biopharmaceutical company that develops innovative therapeutics aimed at treating serious and life-threatening diseases by targeting molecular pathways involved in cellular metabolism and inflammation. The company is advancing several clinical trial programs, including bardoxolone methyl for chronic kidney disease related to Alport syndrome and pulmonary arterial hypertension, as well as omaveloxolone for Friedreich’s ataxia. Additionally, Reata is conducting studies for various forms of chronic kidney disease, including IgA nephropathy and diabetic kidney disease. The company is also developing RTA 901 for neurological conditions such as diabetic neuropathy and exploring RORgT inhibitors in preclinical stages for autoimmune and fibrotic diseases. Reata has strategic collaborations with Kyowa Kirin to develop bardoxolone in several Asian markets and with AbbVie to research second-generation Nrf2 activators for various indications. Founded in 2002 and headquartered in Plano, Texas, Reata Pharmaceuticals was previously known as Reata Discovery, Inc. until its name change in 2005.

Semantra makes it possible to have an intelligent conversation with your enterprise databases, immediately improving the value of critical business applications like CRM, BI and ERP solutions. Semantra extends traditional BI and enterprise search applications by empowering users to quickly and easily access precise, critical information contained in enterprise databases through a familiar search box and using the language of your business. The company was founded in 2003 and is based in Addison, Texas. On June 21, 2009, Semantra, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.

Semantra makes it possible to have an intelligent conversation with your enterprise databases, immediately improving the value of critical business applications like CRM, BI and ERP solutions. Semantra extends traditional BI and enterprise search applications by empowering users to quickly and easily access precise, critical information contained in enterprise databases through a familiar search box and using the language of your business. The company was founded in 2003 and is based in Addison, Texas. On June 21, 2009, Semantra, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.

Reata Pharmaceuticals is a clinical-stage biopharmaceutical company that develops innovative therapeutics aimed at treating serious and life-threatening diseases by targeting molecular pathways involved in cellular metabolism and inflammation. The company is advancing several clinical trial programs, including bardoxolone methyl for chronic kidney disease related to Alport syndrome and pulmonary arterial hypertension, as well as omaveloxolone for Friedreich’s ataxia. Additionally, Reata is conducting studies for various forms of chronic kidney disease, including IgA nephropathy and diabetic kidney disease. The company is also developing RTA 901 for neurological conditions such as diabetic neuropathy and exploring RORgT inhibitors in preclinical stages for autoimmune and fibrotic diseases. Reata has strategic collaborations with Kyowa Kirin to develop bardoxolone in several Asian markets and with AbbVie to research second-generation Nrf2 activators for various indications. Founded in 2002 and headquartered in Plano, Texas, Reata Pharmaceuticals was previously known as Reata Discovery, Inc. until its name change in 2005.

Semantra makes it possible to have an intelligent conversation with your enterprise databases, immediately improving the value of critical business applications like CRM, BI and ERP solutions. Semantra extends traditional BI and enterprise search applications by empowering users to quickly and easily access precise, critical information contained in enterprise databases through a familiar search box and using the language of your business. The company was founded in 2003 and is based in Addison, Texas. On June 21, 2009, Semantra, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.